References
- American Diabetes Association. Standards of medical care in diabetes – 2018. Diabetes Care. 2018;41(Suppl. 1):S1–S159.
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary. Endocr Pract. 2017;23(2):207–238.
- Insulin Glargine 4002 Study Investigators, Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086.
- Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716–1730.
- Arnolds S, Kuglin B, Kapitza C, et al. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64(10):1415–1424.
- Pettus J, Santos Cavaiola T, Tamborlane WV, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32(6):478–496.
- Atkin S, Javed Z, Fulcher G. Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Ther Adv Chronic Dis. 2015;6(6):375–388.
- Lilly. BASAGLAR® (insulin glargine injection 100 units/mL). A long-acting basal insulin, is now available in U.S. Dec 2016. [cited 2017 Nov]. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=1004325
- FDA. FDA approves Basaglar, the first ‘follow-on’ insulin glargine product to treat diabetes. [cited 2017 Nov]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm477734.htm
- Lajara R, Cengiz E, Tanenberg RJ. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes. Curr Med Res Opin. 2017;33(6):1045–1055.
- International Diabetes Federation. Global guideline for type 2 diabetes. 2012. [cited 2017 Nov]. Available from: http://www.idf.org/guideline-type-2-diabetes
- Swinnen SG, Simon ACR, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;(7):CD006383.
- Becker RH, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17(3):261–267.
- Pan C, Gross JL, Yang W, et al. A multinational, randomized, open-label, treat-to-target trial comparing insulin degludec and insulin glargine in insulin-naïve patients with type 2 diabetes mellitus. Drugs R D. 2016;16(2):239–249.
- Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–2762.
- Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235–3243.
- Hollander P, King AB, Del Prato S, et al. Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy. Diabetes Obes Metab. 2015;17(2):202–206.
- Rodbard HW, Cariou B, Zinman B, et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013;30(11):1298–1304.
- Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464–2471.
- Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–1507.
- Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–732.
- Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2017 Sep 15. [Epub ahead of print]. DOI:10.1007/s00125-017-4423-z
- Hollander P, Cooper J, Bregnhøj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976–1987.
- Asias BD, Stock EM, Small NL, et al. Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes. J Diabetes Metab Disord. 2015;14:53.
- Porcellati F, Lucidi P, Bolli GB, et al. Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. Diabetes Care. 2013;36(12):3860–3862.
- Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016;12:389–400.
- Levemir. Prescribing information. [cited 2017 Nov]. Available from: http://www.novo-pi.com/levemir.pdf.
- Toujeo. Prescribing information. [cited 2017 Nov]. Available from: http://products.sanofi.us/toujeo/toujeo.pdf.
- Tresiba. Prescribing information. [cited 2017 Nov]. Available from: http://www.novo-pi.com/tresiba.pdf.
- Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16–38.
- Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858–871.
- Lansang MC, Umpierrez GE. Inpatient hyperglycemia management: a practical review for primary medical and surgical teams. Cleve Clin J Med. 2016;83(5 Suppl 1):S34–S43.
- Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1. Diabetes Care. 2015;38(4):637–643.
- Vora J, Cariou B, Evans M, et al. Clinical use of insulin degludec. Diabetes Res Clin Pract. 2015;109(1):19–31.
- Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17(3):254–260.
- Basaglar. Prescribing information. [cited 2017 Nov]. Available from: http://pi.lilly.com/us/basaglar-uspi.pdf.
- Levemir. Summary of product characteristics. [cited 2107 Nov]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000528/WC500036662.pdf.
- Lantus. Summary of product characteristics. [cited 2107 Nov]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf.
- Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia. 2008;51(3):408–416.
- Meneghini L, Kesavadev J, Demissie M, et al. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:729–736.
- Bryant GA, McDanel DL, Horner KE, et al. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir. Pharmacotherapy. 2013;33(1):56–62.
- Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25(6):542–548.
- Wysham CH, Bhargava A, Chaykin LB, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes. The SWITCH 2 randomized clinical trial. JAMA. 2017;318(1):45–56.
- Toujeo. Summary of product characteristics. [cited 2017 Nov]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000309/WC500047935.pdf.
- Kalra S, Gupta Y. Clinical use of insulin degludec: practical experience and pragmatic suggestions. N Am J Med Sci. 2015;7(3):81–85.
- Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536–2542.
- Lantus. Prescribing Information. [cited 2017 Nov]. Available from: http://products.sanofi.us/lantus/lantus.html.
- Wei W, Zhou S, Miao R, et al. Much ado about nothing? A real-world study of patients with type 2 diabetes switching basal insulin analogs. Adv Ther. 2014;31(5):539–560.
- Levin P, Wei W, Miao R, et al. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. Diabetes Obes Metab. 2015;17(3):245–253.
- Okada M, Okada M, Nishigami J, et al. Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus. J Pharm Health Care Sci. 2015;1:26.
- Wilkins AR, Venkat MV, Brown AS, et al. Patient perspectives on biosimilar insulin. J Diabetes Sci Technol. 2014;8(1):23–25.
- GoodRx. [cited 2017 Nov]. Available from: https://www.goodrx.com.
- DailyMed US National library of medicine. [cited 2017 Nov]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d38d65c1-25bf-401d-9c7e-a2c3222da8af.
- Sanofi. How to use your Lantus Solostar pen. [cited 2017 Nov]. Available from: https://www.lantus.com/using-lantus/using-the-solostar-pen.
- Novolin N. Prescribing information. [cited 2017 Nov]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019959s073lbl.pdf.
- Centers for Disease Control and Prevention. 2016. [cited 2017 Nov]. Available from: https://www.cdc.gov/nchs/fastats/health-expenditures.htm.
- Hua X, Carvalho N, Tew M, et al. Expenditures and prices of antihyperglycemic medications in the United States: 2002–2013. JAMA. 2016;315(13):1400–1402.
- American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033–1046.
- Ng M, Fleming T, Robinson M, et al. Global, regional and national prevalence of overweight and obesity in children and adults 1980–2013: a systematic analysis. Lancet. 2014;384(9945):766–781.
- Liu L, Simon B, Shi J, et al. Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: evidence on health outcomes and antidiabetic treatment in United States adults. World J Diabetes. 2016;7(18):449–461.
- WHO Global Report on Diabetes. 2016. [cited 2017 Nov]. Available from: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf.
- Ramsey L. A cheaper version of the lifesaving diabetes medication just launched in the US. Business Insider. 2016 Dec 15. [cited 2017 Nov]. Available from: http://uk.businessinsider.com/insulin-cheaper-generic-2016-12?r=US&IR=T
- UnitedHealthcare. Your 2017 prescription drug list. Aug 2016. [cited 2017 Nov]. Available from: https://www.uhc.com/content/dam/uhcdotcom/en/Pharmacy/PDFs/Traditional3TierPlans.pdf
- Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734–741.
- Linnebjerg H, Lam EC, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38:2226–2233.
- Ilag LL, Deeg MA, Costigan T, et al. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18:159–168.
- Humulin. Prescribing information. [cited 2017 Nov]. Available from: http://pi.lilly.com/us/HUMULIN-N-USPI.pdf.
- Heinemann L. Biosimilar insulin and costs: what can we expect? J Diabetes Sci Technol. 2016;10(2):457–462.
- Ye F, Rishi A, Kaur A, et al. Real-world assessment of patient characteristics and clinical outcomes of early users of the new insulin glargine 300 U/mL. Diabetes. 2016;65(Suppl. 1):A243.
- Tsai A. The rising cost of insulin. Diabetes Forecast. 2016 Mar. [cited 2017 Nov]. Available from: http://www.diabetesforecast.org/2016/mar-apr/rising-costs-insulin.html
- Tylee T, Hirsch IB. Costs associated with using different insulin preparations. JAMA. 2015;314(7):665–666.
- Rys P, Wojciechowski P, Rogoz-Sitek A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol. 2015;52(4):649–662.
- Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD005613.
- FDA. Information regarding insulin storage and switching between products in an emergency. [cited 2017 Nov]. Available from: http://www.fda.gov/Drugs/EmergencyPreparedness/ucm085213.htm
- Brändle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther. 2011;49(3):217–230.
- Wang L, Wei W, Miao R, et al. Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study. BMJ Open. 2013 Apr 30;3(4):e002348.